Curatis Holding AG (XSWX:CURN) Accounts Receivable : CHF1.12 Mil (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Curatis Holding AG Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Curatis Holding AG's accounts receivables for the quarter that ended in Jun. 2024 was CHF1.12 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Curatis Holding AG's Days Sales Outstanding for the quarter that ended in Jun. 2024 was 103.47.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Curatis Holding AG's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was CHF-2.00.

Curatis Holding AG Accounts Receivable Historical Data

The historical data trend for Curatis Holding AG's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG Accounts Receivable Chart

Curatis Holding AG Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Receivable

Curatis Holding AG Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Accounts Receivable	Get a 7-Day Free Trial			-	-	-	-	1.12

Curatis Holding AG Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Curatis Holding AG Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Curatis Holding AG's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.122	/	1.979	*	91
=	103.47

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Curatis Holding AG's accounts receivable are only considered to be worth 75% of book value:

Curatis Holding AG's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(3.463	+	0.75 * 1.122	+	0.5 * 1.316	-	13.718
-	0	-	0)	/	4.384
=	-2.00

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Curatis Holding AG Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Curatis Holding AG's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Curatis Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (XSWX:CURN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

CURNz:UK

Address

Weierweg 7, Liestal, CHE, CH-4410

Website

https://www.curatis.com

Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.